• Save
09 CeoMeeting- Session 4- Chakra
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

09 CeoMeeting- Session 4- Chakra

on

  • 530 views

Session 4: Health & Wellness

Session 4: Health & Wellness

Title: The Changing Face Of Healthcare:
Where Are The Opportunities?

Mr Peter Wulff, Sentinext Therapeutics;

Statistics

Views

Total Views
530
Views on SlideShare
529
Embed Views
1

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 1

http://www.slideshare.net 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Short intro to myself and or the company (whatever not said by John).Definition of CRO.“Global company headquartered in Penang”The main point I’d like to make today is that whatever the changes in the macro environment for health care, we as industry participants must focus on delivering benefits to patients.Productivity crisis
  • I want to show you something and then explain why it is important to the future of human health. But first a little background – one slides of background to be exact.Many of you will be familiar with the concept of using laboratory animal, particularly rodents in drug research. In my line of work discovering and developing new drugs, I have often had to ask myself – are human more like mice, or more like rats, or more like ferrets, or more like mini pigs or like …………….These are important decision we need to make when developing safe effective drugs.Right at the beginning of the R&D for a new drug scientists study human diseases. Then once they understand the diseases they try to create new chemicals to modify or cure these diseases. Once a promising chemical is identified, then the long and difficult process of drug development commences.In some diseases there are good models to predict efficacy – like antibiotics. We understand that bacteria cause the disease and we can use models to check if new antibiotics kill the bacteria. But even then, drugs showing efficacy still only get to market some of the time. Still we consider these models predictive enough.The area we help companies in, schizophrenia is very hard. It is not well understood what causes the disease – some genetic components + some environmental components, there are different types of symptoms which seem to lie on a spectrum and different drugs work only in some patients and all the available drugs have dramatic side effects. There is a compelling need for better drugs in this area and the current models used by industry do not give good productivity so many drugs are taken into development and into clinical trials only to find they do not work – they don’t offer benefit to patients. This process costs 10’s to 100’s of millions of dollars. This represents a colossal waste for companies and no benefit to patients.The global market for antipsychotic medication is ~USD15b, 17 of the top 20 pharma companies have R&D programs in this area and many small pharma and biotech companies also research in this area.So what we have is a way to predict how drugs will behave in people very early in development before lots of time and money are wasted. This is the value proposition we bring to the global pharmaceutical industry.The ‘buzz word’ for what we do is translational medicine – we are definitely on the bench side of the equation of allowing early discoveries to be translated into patient benefits.How this translates into opportunities for Malaysia – “global company headquartered in Penang” theme
  • Explain VideoFinally it seems like we have a good way to predict which drugs to spend time and money developing.
  • In any business is it important to understand the full value chain. In our case we have identified we are focused on benefit to patients but in between it is important to understand how the industry works.Explain slide.We need to help each group along the way to get all the way around the chain and have better drugs in the hands of patients.
  • Pharma industry needs to be more productive with its R&D to address its most pressing challenges. I hope by riding three waves I can get to where I want to be commercially easier.Unmet patient needs – we are helping industry address this issue by helping them be more productive.Outsourcing: way for companies to reduce fixed costs and to access specialist knowledge.Asia: way to get access to the enormous talent pool.Helping patients with a serious and debilitating diseases is a good reason to get out of bed each morning. Along the way, we hope we can also benefit our shareholders, our staff and our community.

09 CeoMeeting- Session 4- Chakra Presentation Transcript

  • 1. Helping our customers to improve the lives of psychiatric patients by offering the most predictive in-vivo screens to discover the next generation of therapeutic compounds
    Suite 016/018, Kompleks EUREKA, Universiti Sains Malaysia, 11800 Penang, Malaysia
    Tel: +604-659 1926 • Fax: +604-659 1927 • www.chakrabiotech.com.my
  • 2. Discovery Pharmacology
    2
    How can we be sure the drug is safe and effective enough to warrant:
    1. Risks to volunteers/patients 2. Development risks?
    Current medications
    “Clearly the treatment armamentarium is by no means complete or satisfactory, and individuals require more, not fewer options.” US FDA
    “The improvement in medication has not changed the proportion of schizophrenics who maintain a steady job, about 10% - about the same proportion who suicide.” Neuroinvestments
  • 3. Key Technology (1/2)
    3
  • 4. Key Technology (2/2)
    4
  • 5. The Pharma Value Chain
    5
  • 6. Chakra Biotech Sdn Bhd
    2007 - Founded
    Spin-out of discovery platform to allow commercialisation
    Granted Bionexus status from the Malaysian Biotech Corporation (MBC) in 2007
    2008 - Funded
    Awarded Seed Fund Commercialisation Grant of RM2.5m
    Obtained venture capital funding from MLSCF and MTDC
    2009 – Building platform
    Chakra Biotech was officially opened 11th March 2009 by the Fadilah Yusof, Deputy Minister for Science, Technology and Innovation on behalf of the Minister
    First revenues
    2010 - Expansion
    Major expansion of capacity and further research planned for 2010
    6
  • 7. Opportunities for Malaysia
    Waves of Opportunity
    Unmet patients needs: drives pharma
    Outsourcing: increasing by ~15% p.a.
    Asia: increasing importance for R&D and markets
    Malaysia – Catching the Waves
    Attention - earliest part of pharma value chain
    Employment – more than scientists
    7